Ligand Pharma's total assets for Q3 2025 were $1.48B, an increase of 55.68% from the previous quarter. LGND total liabilities were $526.60M for the fiscal quarter, a 338.56% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.